C4 Therapeutics (CCCC) FY Conference Transcript

Summary of C4 Therapeutics (CCCC) FY Conference Call - January 09, 2023 Company Overview - C4 Therapeutics is a leader in targeted protein degradation, aiming to create transformative medicines for patients [1][2] - The company has a world-class degrader platform that focuses on designing orally bioavailable and chemically efficient degraders [2][4] Core Strategies and Achievements - The strategy is built on three pillars: advancing the oncology portfolio, investing in discovery, and expanding the platform's applicability beyond cancer [5][6] - In 2022, C4 initiated work on seven new targets and has four programs in the clinic, with three currently in clinical trials and one expected to enter this year [5][7] Clinical Programs 1. CFT7455: Targets IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin's lymphoma - Aims to be a backbone therapy, reducing off-target toxicity and overcoming resistance seen with existing treatments [12][13] - Phase I data showed a half-life of approximately 48 hours, leading to adjustments in dosing schedules [15][16] - Expected to share Phase I dose escalation data in the second half of 2023 [18] 2. CFT8634: Targets BRD9 for synovial sarcoma and SMARCB1 deleted tumors - Designed to be orally bioavailable and potent, with a Phase III study initiated in May 2022 [22][27] - Initial data shows promising pharmacokinetics and pharmacodynamics, with a 13-hour half-life [23][24] - Data readouts expected in the second half of 2023 [23] 3. CFT1946: Targets BRAF V600 mutations for melanoma, colorectal cancer, and non-small cell lung cancer - Aims to address resistance mutations associated with current BRAF inhibitors [29][30] - Clinical trial started in late 2022, with ongoing escalation expected throughout 2023 [31][32] 4. CFT8919: Targets EGFR L858R mutations for non-small cell lung cancer - Designed to bind to an allosteric site specific to the L858R mutation, allowing efficacy against resistance mutations [33][34] - IND submission planned for 2023 [36] Market Position and Competitive Landscape - C4 Therapeutics emphasizes the unique advantages of its degrader platform compared to existing therapies, particularly in terms of efficacy and safety profiles [54][56] - The company is aware of emerging competitors in the space and is focused on differentiating its products through superior clinical data [55][56] Financial Outlook - The company is funded through the end of 2024 to achieve its clinical milestones [37] Additional Insights - The company is exploring additional indications for BRD9 beyond the initial targets due to emerging biology [27] - The safety profile of the BRD9 program has been satisfactory, with no dose-limiting toxicities reported in early cohorts [41][44] - C4 Therapeutics is committed to optimizing patient enrollment strategies across its clinical trials [49] This summary encapsulates the key points from the conference call, highlighting the company's strategic focus, clinical advancements, and market positioning.